Piribedil (BioDeep_00000858590)

代谢物信息卡片

Piribedil

化学式: C16H18N4O2 (298.1429688)
中文名称: 吡贝地尔
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1(N2CCN(CC3=CC=C(OCO4)C4=C3)CC2)=NC=CC=N1
InChI: InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2

描述信息

D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents
N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists
C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist
Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers[1][2][3][4].

同义名列表

1 个代谢物同义名

Piribedil

数据库引用编号

8 个数据库交叉引用编号

ChEBI: CHEBI:92833
KEGGdrug: D07305
PubChem: 4850
DrugBank: DB12478
ChEMBL: CHEMBL1371770
MeSH: Piribedil
CAS: 3605-01-4
medchemexpress: HY-12707

分类词条

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

文献列表

Chandra Teja Uppuluri, Punna Rao Ravi, Avantika V Dalvi. Design and evaluation of thermo-responsive nasal in situ gelling system dispersed with piribedil loaded lecithin-chitosan hybrid nanoparticles for improved brain availability. Neuropharmacology. 2021 12; 201(?):108832. doi: 10.1016/j.neuropharm.2021.108832. [PMID: 34627852]
Chandra Teja Uppuluri, Punna Rao Ravi, Avantika V Dalvi. Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson's disease. International journal of pharmaceutics. 2021 Sep; 606(?):120881. doi: 10.1016/j.ijpharm.2021.120881. [PMID: 34273426]
Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
Chandra Teja Uppuluri, Avantika V Dalvi, Ekta Prasanthi Bommireddy, Punna Rao Ravi. Development and validation of rapid and sensitive LC methods with PDA and fluorescence detection for determination of piribedil in rat plasma and brain tissues and their pharmacokinetic application. Biomedical chromatography : BMC. 2018 Oct; 32(10):e4303. doi: 10.1002/bmc.4303. [PMID: 29851104]
Nishikant Wase, Boqiang Tu, James W Allen, Paul N Black, Concetta C DiRusso. Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae. Plant physiology. 2017 Aug; 174(4):2146-2165. doi: 10.1104/pp.17.00433. [PMID: 28652262]
Jie Zhang, Yun-zhi Ma, Xiao-ming Shen. Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial. Journal of integrative medicine. 2013 Jul; 11(4):285-90. doi: 10.3736/jintegrmed2013035. [PMID: 23867247]
Mary A Fletcher, Martin Rosenthal, Michael Antoni, Gail Ironson, Xiao R Zeng, Zachary Barnes, Jeanna M Harvey, Barry Hurwitz, Silvina Levis, Gordon Broderick, Nancy G Klimas. Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome. Behavioral and brain functions : BBF. 2010 Dec; 6(?):76. doi: 10.1186/1744-9081-6-76. [PMID: 21190576]
Melike Uner, Gülgün Yener. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. International journal of nanomedicine. 2007; 2(3):289-300. doi: NULL. [PMID: 18019829]
Incilay Süslü, Sacide Altinöz. A reversed-phase high-performance liquid chromatographic method for the determination of zafirlukast in pharmaceutical formulations and human plasma. Journal of AOAC International. 2006 Nov; 89(6):1557-64. doi: 10.1093/jaoac/89.6.1557. [PMID: 17225602]
Dag Nyholm. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. Clinical pharmacokinetics. 2006; 45(2):109-36. doi: 10.2165/00003088-200645020-00001. [PMID: 16485914]
Hosny Ibrahim. Chemically modified carbon paste electrode for the potentiometric flow injection analysis of piribedil in pharmaceutical preparation and urine. Journal of pharmaceutical and biomedical analysis. 2005 Jul; 38(4):624-32. doi: 10.1016/j.jpba.2005.02.006. [PMID: 15967290]
Nicolas Simon, Joëlle Micallef, Jean-Charles Reynier, Monique Lesourd, Tatiana Witjas, André Alicherif, Jean-Philippe Azulay, Olivier Blin. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study. Movement disorders : official journal of the Movement Disorder Society. 2005 Jul; 20(7):803-9. doi: 10.1002/mds.20400. [PMID: 15726579]
Suzy M Sabry, Magda H Barary, Mohamed H Abdel-Hay, Tarek S Belal. Adsorptive stripping voltammetric behaviour of azomethine group in pyrimidine-containing drugs. Journal of pharmaceutical and biomedical analysis. 2004 Feb; 34(3):509-16. doi: 10.1016/s0731-7085(03)00631-9. [PMID: 15127806]
Bengi Uslu, Sibel A Ozkan. Electroanalytical characteristics of piribedil and its differential pulse and square wave voltammetric determination in pharmaceuticals and human serum. Journal of pharmaceutical and biomedical analysis. 2003 Mar; 31(3):481-9. doi: 10.1016/s0731-7085(02)00725-2. [PMID: 12615235]
M Demirel, Y Yazan, R H Müller, F Kiliç, B Bozan. Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. Journal of microencapsulation. 2001 May; 18(3):359-71. doi: 10.1080/02652040010018119. [PMID: 11308226]
L A Smith, M G Jackson, C Bonhomme, C Chezaubernard, R K Pearce, P Jenner. Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset. Clinical neuropharmacology. 2000 May; 23(3):133-42. doi: 10.1097/00002826-200005000-00002. [PMID: 10895396]
J L Montastruc, M Ziegler, O Rascol, M Malbezin. A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 1999 Mar; 14(2):336-41. doi: 10.1002/1531-8257(199903)14:2<336::aid-mds1021>3.0.co;2-9. [PMID: 10091630]
F Calzi, R Bellasio, G Guiso, S Caccia, M T Tacconi. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. European journal of pharmacology. 1997 Nov; 338(2):185-90. doi: 10.1016/s0014-2999(97)81947-4. [PMID: 9456001]
S Sarati, S Caccia. Solid-phase extraction of piribedil and its metabolites from plasma and urine without and after deconjugation, by high performance liquid chromatography. European journal of drug metabolism and pharmacokinetics. 1992 Jul; 17(3):205-11. doi: 10.1007/bf03190147. [PMID: 1490490]
P Jenner. Parkinson's disease: pathological mechanisms and actions of piribedil. Journal of neurology. 1992; 239 Suppl 1(?):S2-8. doi: 10.1007/bf00819559. [PMID: 1634907]
A Luchsinger, M Velasco, A Urbina, J Morillo, E Romero, R Alvarez, O H Pieretti. Comparative effects of dopaminergic agonists on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients. Journal of clinical pharmacology. 1992 Jan; 32(1):55-60. doi: 10.1002/j.1552-4604.1992.tb03788.x. [PMID: 1346790]
S Sarati, G Guiso, R Spinelli, S Caccia. Determination of piribedil and its basic metabolites in plasma by high-performance liquid chromatography. Journal of chromatography. 1991 Feb; 563(2):323-32. doi: 10.1016/0378-4347(91)80038-e. [PMID: 2055995]
S Sarati, G Guiso, S Garattini, S Caccia. Kinetics of piribedil and effects on dopamine metabolism: hepatic biotransformation is not a determinant of its dopaminergic action in rats. Psychopharmacology. 1991; 105(4):541-5. doi: 10.1007/bf02244377. [PMID: 1771223]
L De Marinis, A Mancini, F Calabrò, R Sciuto, C Fiumara, P Zuppi, A Saporosi, A Barini, E Menini. Evaluation of dopaminergic tone in postmenopausal women: effects of piribedil on anterior pituitary hormones. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 1991 Jan; 23(1):30-4. doi: 10.1055/s-2007-1003604. [PMID: 1849868]
S Regunathan, K Missala, T L Sourkes. Central regulation of adrenal tyrosine hydroxylase: effect of induction on catecholamine levels in the adrenal medulla and plasma. Journal of neurochemistry. 1989 Dec; 53(6):1706-10. doi: 10.1111/j.1471-4159.1989.tb09234.x. [PMID: 2572679]
M Ekker, T L Sourkes, R Gabor. Reduced amounts of S-adenosylmethionine decarboxylase in the adrenal glands of rats following administration of piribedil or 2-deoxyglucose. Biochemical pharmacology. 1988 Oct; 37(19):3613-8. doi: 10.1016/0006-2952(88)90392-9. [PMID: 3178874]
R Guillaume, G Charles, P Mesters, M Schittecatte, J Wilmotte. [Stimulation of somatotropin hormone by piribedil, a dopaminergic agonist, in endogenous depression. Preliminary study]. Acta psychiatrica Belgica. 1988 Mar; 88(2):153-61. doi: NULL. [PMID: 2905110]
C E McCoy, F L Douglas, L I Goldberg. Selective antagonism of the hypotensive effects of dopamine agonists in spontaneously hypertensive rats. Hypertension (Dallas, Tex. : 1979). 1986 Apr; 8(4):298-302. doi: 10.1161/01.hyp.8.4.298. [PMID: 2870024]
M Dóda, L György. Dopaminergic inhibition of sympathetic activity in the cat. Polish journal of pharmacology and pharmacy. 1985 May; 37(3):397-404. doi: NULL. [PMID: 4070081]
D K Sarkar, P E Gottschall, J Meites. Decline of tuberoinfundibular dopaminergic function resulting from chronic hyperprolactinemia in rats. Endocrinology. 1984 Oct; 115(4):1269-74. doi: 10.1210/endo-115-4-1269. [PMID: 6479093]
L De Marinis, A Mancini, F Calabrò, M Massari, M Torlontano, A Barbarino. Differential effects of a dopaminergic drug (piribedil) on pituitary hormone release in normal men and women. Acta endocrinologica. 1983 Dec; 104(4):385-9. doi: 10.1530/acta.0.1040385. [PMID: 6419519]
V I Reus, C R Lake, R M Post. Effect of piribedil (ET-495) on plasma norepinephrine: relationship to antidepressant response. Communications in psychopharmacology. 1980; 4(3):207-13. doi: NULL. [PMID: 7226752]
C Chevillard, M N Mathieu, D Recommis. Prejunctional actions of piribedil on the isolated kidney of the rabbit: comparison with apomorphine. British journal of pharmacology. 1980; 71(2):513-8. doi: 10.1111/j.1476-5381.1980.tb10965.x. [PMID: 7470760]
R M Post, D C Jimerson, W E Bunney. Perspectives in the treatment of the psychoneurological disorders: affective disorders. Progress in neuro-psychopharmacology. 1979; 3(1-3):65-74. doi: 10.1016/0364-7722(79)90071-7. [PMID: 45566]
E Vijayan, L Krulich, S M McCann. Catecholaminergic regulation of TSH and growth hormone release in ovariectomized and ovariectomized, steroid-primed rats. Neuroendocrinology. 1978; 26(3):174-85. doi: 10.1159/000122779. [PMID: 683468]
E E Müller, A R Genazzani, S Murru, P Fioretti. Effect of piribedil on plasma prolactin levels in women with puerperal or pathological hyperprolactinaemia. Acta endocrinologica. 1977 Sep; 86(1):33-41. doi: 10.1530/acta.0.0860033. [PMID: 578612]
S V Drouva, R V Gallo. Further evidence for inhibition of episodic luteinizing hormone release in ovariectomized rats by stimulation of dopamine receptors. Endocrinology. 1977 Mar; 100(3):792-8. doi: 10.1210/endo-100-3-792. [PMID: 95702]
S Forconi, M Guerrini, D Agnusdei, T Di Perri. [Effect of an infusion of piribedil in normal subjects and in patients with peripheral obliterating arterial disease on the blood flow of the lower limbs and on blood, plasma and serum viscosity]. Minerva medica. 1976 May; 67(25):1671-80. doi: NULL. [PMID: 934519]
E Marmo. [Pharmacology of piribedil]. Minerva medica. 1976 May; 67(25):1628-47. doi: NULL. [PMID: 934518]
G P Mueller, J Simpkins, J Meites, K E Moore. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats. Neuroendocrinology. 1976; 20(2):121-35. doi: 10.1159/000122476. [PMID: 958594]
R Horowski, H J Gräf. Influence of dopaminergic agonists and antagonists on serum prolactin concentrations in the rat. Neuroendocrinology. 1976; 22(3):273-86. doi: 10.1159/000122634. [PMID: 1028957]
L I Goldberg. Comparison of putative dopamine receptors in blood vessels and the central nervous system. Advances in neurology. 1975; 9(?):53-6. doi: NULL. [PMID: 238377]
F Camanni, F Massara, V Fassio, G M Molinatti, E E Müller. Effect of five dopaminergic drugs on plasma growth hormone levels in acromegalic subjects. Neuroendocrinology. 1975; 19(3):227-40. doi: 10.1159/000122443. [PMID: 1223659]